A Study to Learn More About Improving Mesenchymal Stem Cells and Its Application in Chronic Kidney Disease Due to Hypertensive Nephropathy


About this study

The purpose of this study is to investigate the central hypothesis that autologous, adipose-derived MSC preconditioned by hypoxia will have superior kidney angiogenic function compared to untreated MSC from humans with HN and CKD.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

All subjects eligible for this study will meet the following inclusion criteria:

  • Age between 18 to 80 years
  • Estimated GFR ≥15 mL/min/1.73m²
  • Ability to provide consent and complete all aspects of the study

Exclusion Criteria: 

  • Subjects will be excluded from participation if they have any of the following exclusion criteria:
  • Diabetes Mellitus
  • Pregnant
  • Evidence of hepatitis B or C, or HIV infection (this will be assessed through the EMR)
  • Solid organ transplantation
  • Nephrotic syndrome
  • Immunosuppression therapy
  • Active glomerulonephritis
  • Autosomal dominant or recessive polycystic kidney disease
  • Known RVD
  • Active malignancy to minimize interference of underlying conditions or treatments on MSC functionality.
  • Subjects on therapeutic doses of anticoagulants [Rivaroxaban (Xarleto); Apixaban (Eliquis); Dabigatran (Pradaxa, Prazaxa)].
  • History of substance abuse (including alcohol) within the past 2 years
  • Active substance abuse (>3 alcoholic beverages/day or>21 per week)
  • Body weight >150 kg or BMI >50
  • Uncontrolled psychiatric disorder

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sandra Herrmann, M.D.

Closed for enrollment

Contact information:

Department of Medicine – Clinical Trials Unit

(507) 266-1944


More information


Publications are currently not available

Mayo Clinic Footer